AIM
SRPT icon

Assured Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Assured Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8,477
Closed -$251K – 702
2017
Q1 		$251K Buy
+8,477
New +$262K 0.01% 505

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assured Investment Management's SRPT Position: Q2 2017 in Review

Assured Investment Management sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 8,477 shares — an estimated $251K sold.

Assured Investment Management first reported a position in SRPT in Q1 2017 and held it in 1 quarter. The position peaked at $251K in Q1 2017. 189 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

  • Assured Investment Management reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Assured Investment Management sold 8,477 Sarepta Therapeutics shares in Q2 2017, an estimated $251K.
  • Assured Investment Management first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 1 quarter.
  • Assured Investment Management's Sarepta Therapeutics position peaked at $251K in Q1 2017.
  • 189 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Assured Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.